| Biomarker ID | 1844 |
| PMID | 30890858 |
| Year | 2019 |
| Biomarker | RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Stage T2a Vs T2b |
| Type of Biomarker | Prognostic |
| Cohort | 14 patients had tumor stage T1c, 10 had T2, 23 had T2a, 11 had T2b, 30 had T2c, 2 had T3, 6 had T3a, 8 had T3b, 1 had T4. Dataset: Long et. all |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.826 |
| Accuracy | 85.3% |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |